Clinical Trial Update: A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study (INSIGNIA-PAH) evaluated the inhaled sGC stimulator Frespaciguat (MK-5475) for pulmonary arterial hypertension; the trial is completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• Frespaciguat

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pulmonary Arterial Hypertension, Hypertension, Pulmonary | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-02-21